drugset / Trial / NCT00723606

A Randomized, Open-Label, Multi-Center Study To Evaluate The Efficacy And Safety Of Intramuscular Ziprasidone In Patients With Agitation

NCT00723606

Phase 3 Completed 376 enrolled Viatris Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

This local registration study is to confirm the hypothesis of the efficacy, tolerability and safety of ziprasidone IM (intramuscular) in the Chinese population with agitation in schizophrenia

Timeline

Start
2008-09
Primary completion
2009-07
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Haloperidol Other / unclassified 5 mg Intramuscular
Subject Ziprasidone Small molecule 10 mg Intramuscular
Subject Ziprasidone Small molecule 20 mg Intramuscular

Indications